Peripheral neuropathy damages peripheral nerves, causing pain, numbness, or weakness, usually in the feet and hands. Causes include diabetes, infections, trauma, or idiopathic (unknown) origins. Treatment aims to manage pain, halt progression, and restore function where possible.
Identifying and treating the underlying cause is paramount: tight glycaemic control in diabetes, vitamin supplementation (B12, folate, thiamine) if deficiency exists, or cessation of causative medications. For pain management, first-line oral options include gabapentin or pregabalin (anticonvulsants that modulate nerve signalling); these are effective for neuropathic pain in 30–50% of patients. Topical capsaicin cream or lidocaine patches applied directly to affected skin provide localised relief. Tricyclic antidepressants (amitriptyline, nortriptyline) are second-line and effective for many. For severe pain unresponsive to oral medication, nerve blocks or spinal cord stimulation (SCS) implants deliver targeted relief. Physiotherapy and occupational therapy improve function and prevent falls. Managing associated conditions (blood pressure, cholesterol) slows progression.
Acupuncture is used for neuropathic pain; evidence is mixed and effects are variable. Alpha-lipoic acid, a natural antioxidant, has some evidence for diabetic neuropathy, particularly in German studies, though US and EU trials are less conclusive. B-vitamin complexes (B6, B12, folate) support nerve health if deficiency exists. Low-level laser or LED therapy may reduce pain with modest evidence. Transcutaneous electrical nerve stimulation (TENS) units offer temporary symptom relief. Hyperbaric oxygen therapy is used off-label but evidence is limited.
Stem-cell therapies are under investigation for peripheral neuropathy, particularly in diabetic and chemotherapy-induced neuropathy. Bone-marrow or adipose-derived mesenchymal stem cells injected systemically or locally may reduce inflammation, promote nerve regeneration, and improve pain and sensory function. Several clinical trials are in progress, with preliminary data suggesting benefit. These remain investigational and are not yet standard care. Candidacy depends on neuropathy type, severity, and failure of conventional treatment. See regenerative neuropathy options and candidacy evaluation.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Gabapentin or pregabalin (oral) | Standard | Strong | €20–100/month | Low | Ongoing; 1–4 weeks to effect |
| Topical capsaicin or lidocaine | Standard | Strong | €15–40/month | Low | None; apply as needed |
| Tricyclic antidepressants (amitriptyline) | Standard | Strong | €5–30/month | Low | Ongoing; 2–4 weeks benefit |
| Nerve blocks or spinal cord stimulation | Standard | Moderate | €500–15,000 | Medium–High | Few days to weeks per procedure |
| Glycaemic control (diabetes-related) | Standard | Strong | €50–200/month | Low | Ongoing; slows progression |
| Alpha-lipoic acid supplement | Alternative | Moderate | €20–60/month | Low | Ongoing; 12 weeks trial |
| Acupuncture | Alternative | Limited | €50–80 per session | Low | None; multiple sessions needed |
| Stem-cell therapy | Regenerative | Investigational | €4,000–15,000 | Low–Medium | Few days; ongoing research |
Hyperglycaemia damages nerves directly through metabolic stress and inflammation. Tight glycaemic control (HbA1c target <7%) slows or halts neuropathy progression. Early intervention is most effective; once severe nerve damage occurs, control cannot fully reverse it, but prevents further deterioration.
Full benefit typically emerges within 1–4 weeks, though some relief may be felt within days. Doses are typically titrated upward gradually to minimise side effects (dizziness, drowsiness). These medications are effective in about half of patients; if ineffective, alternatives like tricyclic antidepressants or topical treatments are tried.
Early neuropathy caused by reversible factors (nutritional deficiency, medication toxicity) may improve with treatment. However, advanced neuropathic nerve damage is largely irreversible. The goal is to halt progression, manage pain, and maintain function. Some investigational therapies like stem cells aim to regenerate nerves, but evidence is still emerging.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita